胰升糖素样肽-1的研究进展  

Recent progress on glucagon-like peptide-1

作　　者：战云飞[1] 郑少雄[1] 

机构地区：[1]天津医科大学第二医院内分泌代谢科,300211

出　　处：《国际内分泌代谢杂志》2006年第B04期62-64,共3页International Journal of Endocrinology and Metabolism

摘　　要：胰升糖素样肽-1(GLP-1)是由肠道内分泌L细胞分泌的肠促胰岛素,具有促进胰岛素分泌、胰岛细胞生长、增殖和分化并抑制胰岛β细胞凋亡等多种作用,可用来预防和治疗糖尿病,辅助进行胰岛细胞移植,且不引起体重增加和低血糖。但GLP-1可很快被二肽基肽酶Ⅳ降解,限制了其临床应用。目前对长效的GLP-1类似物、二肽基肽酶Ⅳ抑制剂和GLP-1基因治疗的研究已成为热点。Glucagon-like peptide-1 （GLP-1） is a kind of incretin secreted by enteroendocrine L-cells of the gut. It stimulates insulin secretion as well as the growth, proliferation and differentiation of the islet cells and inhibits apoptosis of beta-cells. GLP-1 may be used to prevent and treat diabetes and used as an adjuvant in the transplantation of the islet beta-cells. GLP- 1 rarely causes weight gain and hypoglycemia. But the rapid degradation of GLP-1 by dipeptidyl peptidase Ⅳ restricts its clinical application. Recently, the long acting GLP-1 analogs, dipeptidyl peptidase Ⅳ inhibitors and GLP-1 gene therapy have become the hot topics.

关 键 词：胰升糖索样肽-1 糖尿病 二肽基肽酶Ⅳ 

分 类 号：R587.1[医药卫生—内分泌]